Monopar Therapeutics (MNPR) Share-based Compensation Growth (3y) (2020 - 2026)
Monopar Therapeutics (MNPR) Share-based Compensation Growth (3y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.91% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.95% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.93% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.55% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 30.98% |
| 10 | Monopar Therapeutics | 965.64 Mn | 912.88 Mn | - | 277.40% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 277.40% |
| Dec 31, 2025 | -120.70% |
| Sep 30, 2025 | 247.24% |
| Jun 30, 2025 | 286.34% |
| Mar 31, 2025 | 169.65% |
| Dec 31, 2024 | 134.49% |
| Sep 30, 2024 | -28.09% |
| Jun 30, 2024 | -20.29% |
| Mar 31, 2024 | -3.72% |
| Dec 31, 2023 | -75.97% |
| Sep 30, 2023 | -7.29% |
| Jun 30, 2023 | -6.00% |
| Mar 31, 2023 | -12.95% |
| Dec 31, 2022 | 12.43% |
| Sep 30, 2022 | -5.44% |
| Jun 30, 2022 | -16.02% |
| Mar 31, 2022 | 28.83% |
| Dec 31, 2021 | 14.55% |
| Sep 30, 2021 | 61.40% |
| Jun 30, 2021 | 59.23% |